Plus Therapeutics drug gets FDA orphan designation

Plus Therapeutics has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate targeting pediatric glioma. This designation is granted to therapies intended for rare diseases and offers incentives to encourage development. The FDA's decision recognizes the potential of Plus Therapeutics' treatment for a specific, underserved patient population. This milestone could accelerate the drug's development pathway and bring a new therapeutic option to children battling this form of brain cancer.